JP2024520730A - コロナウイルスに対するウイルス様粒子ワクチン - Google Patents

コロナウイルスに対するウイルス様粒子ワクチン Download PDF

Info

Publication number
JP2024520730A
JP2024520730A JP2023574797A JP2023574797A JP2024520730A JP 2024520730 A JP2024520730 A JP 2024520730A JP 2023574797 A JP2023574797 A JP 2023574797A JP 2023574797 A JP2023574797 A JP 2023574797A JP 2024520730 A JP2024520730 A JP 2024520730A
Authority
JP
Japan
Prior art keywords
sars
protein
subject
cov
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520730A5 (https=
Inventor
ニランジャン カネサ－タサン，
チャールズ リチャードソン，
Original Assignee
アイコサバックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイコサバックス， インコーポレイテッド filed Critical アイコサバックス， インコーポレイテッド
Publication of JP2024520730A publication Critical patent/JP2024520730A/ja
Publication of JP2024520730A5 publication Critical patent/JP2024520730A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023574797A 2021-06-07 2022-06-03 コロナウイルスに対するウイルス様粒子ワクチン Pending JP2024520730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197952P 2021-06-07 2021-06-07
US63/197,952 2021-06-07
PCT/US2022/032201 WO2022260960A1 (en) 2021-06-07 2022-06-03 Virus-like particle vaccine for coronavirus

Publications (2)

Publication Number Publication Date
JP2024520730A true JP2024520730A (ja) 2024-05-24
JP2024520730A5 JP2024520730A5 (https=) 2025-06-10

Family

ID=84425412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574797A Pending JP2024520730A (ja) 2021-06-07 2022-06-03 コロナウイルスに対するウイルス様粒子ワクチン

Country Status (10)

Country Link
US (1) US20240252621A1 (https=)
EP (1) EP4351638A4 (https=)
JP (1) JP2024520730A (https=)
KR (1) KR20240019213A (https=)
CN (1) CN118159288A (https=)
AU (1) AU2022289462A1 (https=)
CA (1) CA3221041A1 (https=)
IL (1) IL308842A (https=)
MX (1) MX2023014468A (https=)
WO (1) WO2022260960A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
CN121758566A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒e248r蛋白的免疫原性组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585953B2 (en) * 2011-03-22 2017-03-07 Mucosis B.V. Immunogenic compositions in particulate form and methods for producing the same
CN112521511B (zh) * 2020-12-07 2023-03-14 中山大学 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用

Also Published As

Publication number Publication date
US20240252621A1 (en) 2024-08-01
CA3221041A1 (en) 2022-12-15
CN118159288A (zh) 2024-06-07
MX2023014468A (es) 2024-01-17
AU2022289462A1 (en) 2023-12-14
IL308842A (en) 2024-01-01
WO2022260960A1 (en) 2022-12-15
EP4351638A4 (en) 2025-05-14
KR20240019213A (ko) 2024-02-14
AU2022289462A9 (en) 2024-01-04
EP4351638A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
US20250090656A1 (en) Nucleic acid vaccine against the sars-cov-2 coronavirus
WO2021249451A1 (en) Coronavirus vaccine compositions, methods, and uses thereof
BR112020008652A2 (pt) vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
US20250000968A1 (en) Sars-cov-2 spike fused to a hepatitis b surface antigen
US20210353741A1 (en) Vaccine compositions for the treatment of coronavirus
US20250186576A1 (en) Sars-cov-2 subunit vaccine
JP2024520730A (ja) コロナウイルスに対するウイルス様粒子ワクチン
KR20230034936A (ko) 면역 반응을 생성하는 백신, 아쥬반트 및 방법
CA3184406A1 (en) A dna plasmid sars-coronavirus-2/covid-19 vaccine
AU2011360572A1 (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
US20240316183A1 (en) Sars-cov-2 subunit vaccine
US20240197865A1 (en) Compositions and methods for preventing rsv and piv3 infections
KR20240052044A (ko) 코로나바이러스과 바이러스에 의한 감염을 치료 또는 예방하기 위한 바이러스-유사 입자
US20240293532A1 (en) Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use
US20220233682A1 (en) Vaccine compositions for the treatment of coronavirus
JP2024531150A (ja) 呼吸器多核体ウイルスに対するウイルス様粒子ワクチン
KR20250025527A (ko) 파라믹소바이러스용 다가 백신 및 이의 용도
CN116457011A (zh) 用于治疗冠状病毒的疫苗组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250602